<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7104317/results/search/test_trace/results.xml">
  <result pre="of interferon (IFN) induction in response to viral infection. Viral" exact="infection" post="is associated with the appearance in the cell of"/>
  <result pre="[3]. The primary cascade of the body’s response to viral" exact="infection" post="and administration of exogenous dsRNA (recognition, initiation of intracellular"/>
  <result pre="a substance for creation of new drugs for prevention and" exact="treatment" post="of infectious and non-infectious diseases has not been waning"/>
  <result pre="indicates an important role of dsRNA as markers of viral" exact="infection" post="and triggers of the intracellular antiviral reaction. 2 THE"/>
  <result pre="from immunocytes to epithelial cells. Induction of apoptosis in influenza" exact="infection" post="is associated with the NOD receptor [41]; —extracellular dsRNA"/>
  <result pre="with IFN-α) of hepatitis B and C, and also for" exact="treatment" post="of breast cancer [63–65]. According to the classification proposed"/>
  <result pre="the acute phase of viral hepatitis and encephalitis, for the" exact="treatment" post="of influenza and rabies [61, 66]. However, a number"/>
  <result pre="can be used for activation of innate immunity, prevention and" exact="treatment" post="of infectious and neoplastic diseases. It is interesting to"/>
  <result pre="Currently, the drug has been approved in Argentina for the" exact="treatment" post="of severe cases of myalgic encephalomyelitis/chronic fatigue syndrome [76]."/>
  <result pre="analogs it can be used in higher doses for the" exact="treatment" post="of patients with advanced inoperable cancer [83]. The ClinicalTrials.gov"/>
  <result pre="contains information about 97 clinical trials of Hiltonol for the" exact="treatment" post="of oncological diseases of various localization, influenza, severe acute"/>
  <result pre="viral diseases [76]. Hiltonol is an attractive potential drug for" exact="treatment" post="for Ebola haemorrhagic fever [84]. Liposomes are another variant"/>
  <result pre="of PolyICLC, encapsulated in cationic liposomes, to mice prior to" exact="infection" post="with a lethal dose of influenza A virus, provided"/>
  <result pre="non-parenteral use. This is especially attractive in the case of" exact="treatment" post="of infectious diseases, for which the mucous membranes are"/>
  <result pre="intranasal administration of liposomes with PolyICLC before or shortly after" exact="infection" post="of mice with H5N1 influenza virus inhibited viral replication."/>
  <result pre="reproductive and respiratory syndrome virus (PRRSV) conferred higher protection against" exact="infection" post="[99]. An increased cellular immune response was found in"/>
  <result pre="dsRNA as an adjuvant is particular interesting. For example, mucosal" exact="treatment" post="with PolyI: PolyC shortly after vaccination of mice with"/>
  <result pre="expression during the whole experiment (90 days) was observed during" exact="treatment" post="with liposomes containing P5 and PolyI:PolyC. This suggests that"/>
  <result pre="(Japan); Hokkaido University, Sapporo (Japan) Laboratory studies For prophylaxis and" exact="treatment" post="of infectious and oncological diseases 78 PolyI:PolyC, modified Double-stranded"/>
  <result pre="Inc., Philadelphia, PA (USA) Laboratory studies For the prevention and" exact="treatment" post="of infectious and oncological diseases 75, 77 RGIC100 PolyGI:PolyC"/>
  <result pre="bp) Riboxx GmbH (Germany) Laboratory studies For the prevention and" exact="treatment" post="of infectious and oncological diseases 68 Results of preclinical"/>
 </snippets>
</snippetsTree>
